ArticleFrontiers in pharmacology2020
Does Lithium Deserve a Place in the Treatment Against COVID-19? A Preliminary Observational Study in Six Patients, Case Report.
Article in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Joint European policy on the COVID-19 risks for people with mental disorders: An umbrella review and evidence- and consensus-based recommendations for mental and public health.European psychiatry : the journal of the Association of European Psychiatrists · 2022Pooled it
- Bioceramics Based on Li-Modified Bioactive Glasses for Bone Tissue Regeneration.Materials (Basel, Switzerland) · 2026Article
- Immunogenetics of lithium response and psychiatric phenotypes in patients with bipolar disorder.Translational psychiatry · 2024Article
- Can lithium be used in the setting of clozapine commencement in patients with COVID-19 associated neutropenia: A case report.Clinical case reports · 2024Article
- Long COVID: Complications, Underlying Mechanisms, and Treatment Strategies.Archives of microbiology & immunology · 2023Article
- Li-Doped Bioactive Ceramics: Promising Biomaterials for Tissue Engineering and Regenerative Medicine.Journal of functional biomaterials · 2022Review
- Molecular mechanisms and therapeutic effects of different vitamins and minerals in COVID-19 patients.Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS) · 2022Review
- Evaluation of the diagnosis and treatment options for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).Journal of family medicine and primary care · 2022Review
- Antidepressant Drugs and COVID-19: A Review of Basic and Clinical Evidence.Journal of clinical medicine · 2022Review
- Lithium salts as a treatment for COVID-19: Pre-clinical outcomes.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022Article
- Potential mechanisms underlying lithium treatment for Alzheimer's disease and COVID-19.European review for medical and pharmacological sciences · 2022Review
- Efficacy and Safety of Lithium Treatment in SARS-CoV-2 Infected Patients.Frontiers in pharmacology · 2022Article
- Can l-carnitine reduce post-COVID-19 fatigue?Annals of medicine and surgery (2012) · 2022Review
- Psychotropics and COVID-19: An analysis of safety and prophylaxis.L'Encephale · 2021Article
- The neuropsychiatric manifestations of COVID-19: Interactions with psychiatric illness and pharmacological treatment.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Review
- Commentary: Does Lithium Deserve a Place in the Treatment Against COVID-19? A Preliminary Observational Study in Six Patients, Case Report.Frontiers in pharmacology · 2020Article
Corrections and comments
- Commented on by
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lithium has shown the capacity to: a) inhibit the replication of several types of viruses, some of which are similar to the SARS-CoV-2 virus, b) increase the immune response by reducing lymphopenia, and c) reduce inflammation by preventing or reducing the cytokine storm. In the present study, we have treated six patients with severe COVID-19 infection with lithium carbonate. We found that lithium carbonate significantly reduced plasma reactive C-Protein levels, increased lymphocyte numbers and decreased the neutrophil-lymphocyte ratio, improving both inflammatory activity and the immune response in these patients. We propose that lithium carbonate may deserve a place in the treatment against COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.